Review Article

Modelling the functional genomics of Parkinson’s disease in Caenorhabditis elegans: LRRK2 and beyond

Rachael J. Chandler1, Susanna Cogo1,2,Patrick A. Lewis3,4 and Eva Kevei1

1School of Biological Sciences, University of Reading, Reading, RG6 6AH, U.K.; 2Department of Biology, University of Padova, Padova, Via Ugo Bassi 58/B, 35121, Italy; 3Royal Veterinary College, University of London, London, NW1 0TU, U.K.; 4Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, University College London, London, WC1N 3BG, U.K.

Correspondence: Eva Kevei (e.g.kevei@reading.ac.uk)

For decades, Parkinson’s disease (PD) cases have been genetically categorised into familial, when caused by mutations in single genes with a clear inheritance pattern in affected families, or idiopathic, in the absence of an evident monogenic determinant. Recently, genome-wide association studies (GWAS) have revealed how common genetic variability can explain up to 36% of PD heritability and that PD manifestation is often determined by multiple variants at different genetic loci. Thus, one of the current challenges in PD research stands in modelling the complex genetic architecture of this condition and translating this into functional studies. Caenorhabditis elegans provide a profound advantage as a reductionist, economical model for PD research, with a short lifecycle, straightforward genome engineering and high conservation of PD relevant neural, cellular and molecular pathways. Functional models of PD genes utilising C. elegans show many phenotypes recapitulating pathologies observed in PD. When contrasted with mammalian in vivo and in vitro models, these are frequently validated, suggesting relevance of C. elegans in the development of novel PD functional models. This review will discuss how the nematode C. elegans PD models have contributed to the uncovering of molecular and cellular mechanisms of disease, with a focus on the genes most commonly found as causative in familial PD and risk factors in idiopathic PD. Specifically, we will examine the current knowledge on a central player in both familial and idiopathic PD, Leucine-rich repeat kinase 2 (LRRK2) and how it connects to multiple PD associated GWAS candidates and Mendelian disease-causing genes.

Introduction

Parkinson’s disease (PD) is a common, progressive and multi-system neurodegenerative disorder, for which there is currently no disease modifying therapeutic. Affecting 2% of the population over 65 [1], PD is clinically characterised by the development of a progressive resting tremor, bradykinesia and rigidity, responsive to dopamine pathway therapeutics [2–4]. Although predominantly considered a movement disorder, debilitating non-motor symptoms of PD are common in affected individuals and heterogeneous in their presence and extent [2,4–6]. These can include hyposmia, sleep disturbances and autonomic dysfunction, leading to postural hypotension, constipation and urinary incontinence [7]. Psychological conditions such as anxiety and depression have a high incidence throughout PD progression [5–7], along with cognitive impairment, with dementia affecting approximately 60% of individuals 12 years post diagnosis [8]. PD is driven by the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to the cardinal motor symptoms, and neuropathologically distinguished by the accumulation of

© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).
Lewy bodies, protein aggregates mainly composed of fibrillar α-synuclein [9]. At the point of PD diagnosis, α-synuclein pathology in the brain is widespread [9], accounting for the diversity and heterogeneity of non-motor symptoms, with an estimated 80% of dopaminergic neurons in the substantia nigra lost at the onset of diagnostic motor symptoms [7]. Hence, the development of novel, disease modifying therapeutics to halt or slow the progression of PD is an area of extensive research, underpinned by our understanding of cellular pathways perturbed in PD pathogenesis.

The complex aetiology of idiopathic PD is a rapidly expanding area of research, with a plethora of genetic and environmental factors associated with the lifetime risk of PD development [1,10–12]. Approximately 90% of late adulthood-onset PD cases are idiopathic, defined by the absence of an evident monogenic determinant, while the remainder are familial, showing monogenic, Mendelian patterns of inheritance [13]. In most cases, Mendelian PD is symptomatically indistinguishable from the idiopathic disease [13–15], suggesting a potentially shared pathophysiology. PD causative mutations have been identified in a plethora of genes summarised in Figure 1, many of which converge on common pathways including endosomal sorting, vesicle trafficking, lysosomal and mitochondrial function [16]. However, increasing evidence suggests that familial and idiopathic PD can follow an oligogenic pattern of inheritance, in which variants in a number of key genes result in an increased susceptibility to PD onset [17,18]. About 30% of individuals with PD linked to a pathogenic mutation in a Mendelian PD gene also have a concurrent variant in one or more known PD associated genes [18], potentially accounting for variance in disease progression and penetrance between affected individuals. Additionally in post-mortem studies of individuals affected by idiopathic PD with dementia, 23% had more than one genetic variant in known PD associated genes, compared with 10% in an unaffected control population without PD [19]. Importantly, through functional studies of Mendelian disease genes in a diverse range of in vitro, in vivo and in silico models [20,21], substantial progress has been made in elucidating the molecular mechanisms of neurodegeneration in PD.

Common genetic variants identified through genome-wide association studies (GWAS) targeting increased risk of developing idiopathic PD [22] have improved our understanding of the genetic architecture of PD [23–26]. A recent, comprehensive meta-analysis of PD GWASs identified 90 genomic risk signals at 78 genomic loci associated with increased lifetime risk of PD, accounting for up to 36% of heritable risk for PD [24]. Although a great deal of further research is required to conclusively identify the causative variants of these loci, many of the candidate genes converge upon similar cellular pathways shown to be perturbed in Mendelian cases of the disease, notably endocytic vesicle trafficking [16], lysosomal and mitochondrial function [25].

The burden of multiple, common variants within risk loci, which may be present in a single individual, contribute to a polygenic risk score of lifetime PD development [24]. Importantly, a polygenic risk score does not account for environmental factors, which also impact on PD risk and may therefore not be clinically useful in diagnosis, if considered alone [22]. However, when taken in conjunction with prodromal PD symptoms, polygenic risk scores may help in stratifying groups for clinical trials with enhanced genetic precision for targeting, as novel drugs are developed [22]. Identified genes vary in their effect size upon polygenic risk score depending on their functionality, with common variants in known PD associated genes driving larger effect sizes [22,24]. An additional challenge of determining the effect size of novel GWAS loci upon polygenic risk score is that functional modelling for these genes in the context of PD are frequently yet to be undertaken. Thus, our understanding of the mechanism of action of these novel loci and impact upon risk of PD development is incomplete.

The nematode worm, Caenorhabditis elegans (C. elegans), provides an excellent model system for understanding underlying disease biology in neurodegenerative conditions [20,27,28] and is a promising candidate for functional dissection of the complex genetic architecture of PD. Between 60–80% of human genes have orthologues in C. elegans [29] and its genome was the first of any multicellular organism to be completely sequenced [30,31]. Thus, along with the extensive experimental tools available in this system, it facilitates the generation of simple, in vivo gene function models. C. elegans have been widely used as a model for ageing [32], with their short lifespan and rapid reproduction rate facilitating straightforward and fast study of this process. C. elegans are highly amenable to neurobiology, as they have a fully mapped neural connectome [33,34], in which each neuron is characterised in its neurochemistry, connectivity and functionality, often with attributable behavioural phenotypes to each neural circuit to test [35,36]. Furthermore, the majority of neurotransmitters utilised in neuronal signalling in the human brain, are also produced and utilised in the C. elegans neuronal system [30,37,38]. Most Mendelian PD genes have orthologues in C. elegans (Table 1) and multiple models for PD have been developed. These have demonstrated substantial functional conservation with their human counterparts and yielded important insights into gene function [20,21].

C. elegans present a range of PD relevant behavioural and organisational phenotypes to characterise and test, as outputs of gene function, which range from specific dopaminergic neuron attributable behaviours [36,48–50], in vivo microscopy [51], to organisinal responses to environmental stressors [35], as summarised in Figure 2. Comprehensive
Figure 1. The emerging genetic architecture of Parkinson's disease

Mutations and variants in several genes have been identified to be causal or increase susceptibility to PD. Genes indicated in red, which have a very high or causal link with PD development, show Mendelian inheritance and are rare in the population. Genes indicated in orange confer a greater risk of PD development, but with incomplete penetrance. These genes have been identified through both Mendelian and GWAS studies. The expansion of GWAS targeting idiopathic PD has highlighted a plethora of common alleles, illustrated in yellow. These are very common in the population and confer a heightened susceptibility to PD development. Different PD linked mutations in LRRK2 confer varying risk of PD development and penetrance. There are protective variants in LRRK2, which significantly reduce the risk of PD development, highlighting the central role LRRK2 may play in PD pathogenesis.

and recent reviews of PD relevant phenotypes in C. elegans can be found elsewhere [21,35], and open access databases such as WormBase and WormBook contain extensive, up-to-date information on organism genes, C. elegans biology and experimental protocols [52,53]. Functional studies of PD in C. elegans have, to date, been undertaken using gene deletions, RNAi silencing and transgenic overexpression of the human protein of interest (Table 1 and Figure 2) [20,54,55], but the development of CRISPR/Cas9 has enabled the introduction of specific point mutations in C. elegans orthologues [56], for functional modelling from a new perspective.

In this review, we will evaluate the potential modelling approaches of the functional genetics of PD using C. elegans. We angle our focus on the central PD player LRRK2 and its interplay with Mendelian PD genes such as VPS35, which is integral to endosomal function, and the PD hallmark α-synuclein, along with the consistent GWAS locus and potential new therapeutic target, RAB29. The concurrent growth of PD genetics and C. elegans technologies, summarised in Figure 3, opens an expansive window for the development of simple in vivo models, enabling further
Table 1 Mendelian Parkinson's disease genes and their *C. elegans* orthologues

| PD Patient Phenotype | Mendelian PD Gene | Average Age of PD Onset | Number of Confirmed Pathogenic Mutations | Inheritance | GO Biological Functions Disrupted in PD Gene Functional Models | C. elegans Orthologue | C. elegans Models Reported |
|----------------------|------------------|-------------------------|----------------------------------------|-------------|-------------------------------------------------------------|-----------------------|---------------------------|
| Typical PD           | LRRK2            | 58                      | 10                                     | Dominant    | Endosomal Network, Endocytosis, Vesicle trafficking, Microtubules, Lysosomal Function, Macrophagy | irk-1                  | +                         |                          |
|                      |                  |                         |                                        |             |                                                             |                       |                           |
| VPS35                |                  | 50                      | 1                                      |             | Endosomal Network, Endocytosis, Vesicle trafficking, Lysosomal Function | vps-35                | +                         | -                         | +                         |
| SNCA                 |                  | 45                      | 4                                      | Recessive   | Lysosomal stressor                                         | -                     | -                         | +                         |
|                      |                  |                         |                                        |             |                                                             |                       |                           |
| PARKIN               |                  | 31                      | 14                                     | Recessive   | Mitophagy                                                  | pink-1                | +                         | -                         | +                         |
| PARK7                |                  | 58                      | 5                                      |             | Oxidative Stress Response                                  | djp-1.1               | +                         | -                         | +                         |
| Parkinsonism         | DNAJC13          | 67                      | 0                                      | Dominant    | Endosomal Network                                          | djr-1.2               | +                         | -                         | -                         |
|                      |                  |                         |                                        |             |                                                             | rme-8                 | +                         | -                         | +                         |
| DNAJC6               | Juvenile         | 1                       |                                        | Recessive   | Endocytosis                                                | dnj-25                | +                         | -                         | +                         |
| ATP13A2              | Juvenile         | 6                       |                                        | Recessive   | Lysosomal Function                                         | catp-5                | +                         | -                         | +                         |
| SYNJ1                | Early-onset      | 3                       |                                        | Recessive   | Endosomal Network, Endocytosis                              | catp-6                | -                         | -                         | +                         |
|                      |                  |                         |                                        |             |                                                             | catp-7                | -                         | -                         | +                         |
| RAB39B               | Early-onset      | 3                       |                                        | X-linked    | Vesicle Trafficking                                        | unc-26                | +                         | -                         | +                         |
|                      |                  |                         |                                        | Recesive    |                                                             | rab-39                | -                         | -                         | +                         |

Mendelian PD genes with clinical data regarding PD patient phenotype, mode of inheritance and average age of onset are shown with the corresponding orthologue genes in *C. elegans*. Data have been obtained from Mendelian PD clinical studies [1,14,39–46]. The number of confirmed pathogenic mutations has been obtained from NCBI ClinVar database [47], using the filtered by mis-sense and pathogenic mutations filters. ClinVar database lists 10 pathogenic variants for LRRK2, however, of these only 7 variants have been clearly shown to be pathogenic, suggested by multiple reports from independent kindreds. *Caenorhabditis elegans* orthologues have been determined using Ortholist2 search of Mendelian PD genes [29]. Existing *C. elegans* models were obtained from reported phenotype data on each orthologue’s Wormbase entry. GO Biological Functions have been identified utilising G-profiler. Most Mendelian PD genes have an orthologue in *C. elegans*, the gene function of which has been previously studied through either gene deletion, RNAi silencing, transgenic overexpression of the gene or the combination of these methods.

elucidation of gene function and advancing our understanding of PD pathogenesis.

The role of LRRK2 in PD and pleiotropy in neurodegenerative disease

Through candidate gene sequencing and recombination mapping in 46 families with autosomal dominant, late-onset PD, seven coding variants in *LRRK2* have been identified to be causative for PD since the first description of mutations in 2004 (Figure 4) [57–60]. Mutations in *LRRK2* are the most common cause of monogenic PD [13], with
A Quarter Century of advances in human PD genetics, *C. elegans* technologies and functional modelling of Mendelian PD in *C. elegans*

Timeline of advancements in our understanding of PD genetics, from the identification of the first mendelian PD gene encoding for α-synuclein in 1997, to the novel and expanding insights recently gleaned through GWAS. Human PD genes are indicated above the timeline and have individual colours assigned to them, with the milestones in *C. elegans* beneath the timeline indicated with the same colour. Concurrent with the growth of human genetic data in PD, there has been much advancement in *C. elegans* technologies relevant to PD research, illustrated with grey boxes. As a model, *C. elegans* has been pivotal in the development of RNAi technology, whole organism genome sequencing and recently, CRISPR/Cas9 genome editing, enabling the dissection of the effect of point mutations in orthologues. Many of the Mendelian PD genes presented have been studied in *C. elegans* functional models, with promising conservation demonstrated. Some of these are discussed in depth, throughout this review.

Figure 3. A Quarter Century of advances in human PD genetics, *C. elegans* technologies and functional modelling of Mendelian PD in *C. elegans*

© 2021 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC By).
Human LRRK2 and C. elegans LRK-1 share substantial conservation in terms of domain structure, particularly within the catalytic core incorporating the ROC-COR and Kinase domains. The Armadillo domain (ARM), Ankyrin domain (ANK) Leucine Rich Repeats (LRR) and WD40 domain are scaffold regions, facilitating PPIs. Domain information has been obtained from ProSite and Interpro sites, domain visualisation has been generated in DOG1.0 [64]. Sequence alignment has been obtained through analysis of full-length protein sequences with Emboss Needle, pairwise sequence alignment online tool, Matrix: EBLOSUM62, Gap penalty:12, Extend penalty:2 [65–67]. Key residues, that are mutated and pathogenic in PD (labelled with red), and residues, the synthetic mutation of which causes catalytic ablation with demonstrated functional consequences (highlighted in blue) are conserved in C. elegans, with high or similar sequence identity in surrounding residues. Two of the five key autophosphorylation sites found in LRRK2 are also present in LRK-1 (shown with purple labels). Potential emerging roles of the protein in idiopathic PD [61–63]; therefore, it has been intensively investigated for the development of therapeutics [63]. LRRK2 incorporates a Ras-like GTP-ase domain (Ras of complex proteins), known as ROC, with an adjacent C-terminal of ROC, known as COR domain. These are the defining feature of the ROCO protein family, of which LRRK2 is the most studied member. Adjacent to the ROC-COR is a kinase domain [68–70], as shown in Figure 4. LRRK2 also encompasses scaffold armadillo, ankyrin and the eponymous Leucine Rich Repeat (LRR) domains that facilitate protein–protein interactions (PPIs) at the N-terminus and a WD40 terminal domain at the C-terminus [71]. Notably, PD pathogenic mutations are clustered in the catalytic ROC-COR and kinase domain and lead to enhanced kinase activity [72–77], a key molecular hallmark of LRRK2 PD [78], which has attracted great attention from a therapeutic perspective (Clinical Trial ID: NCT03710707 [79], NCT04056689 [80]). Several mutations are located in the ROC domain and disrupt GTP hydrolysis [81–83], thereby increasing the proportion of LRRK2 molecules bound to GTP rather than GDP, enhancing auto and substrate phosphorylation [75,83–88]. The interdependence between GTPase and kinase activities is further supported by evidence that synthetically engineered GTP binding ablation mutations in LRRK2 significantly impair kinase activity in vitro [89,90], although this is not reflected in all models [91,92]. LRRK2 acts as a homodimer [93,94], suggesting that the enzymatic core functions via an interdependent mechanism, with the ROC domain activating the kinase domain when in its GTP bound state [68,86]. This is contentious, as in alternative, well conserved bacterial models, LRRK2 monomerization occurs following GTP binding, but is found as a dimer when GTP bound or nucleotide free [95]. In addition, LRRK2 is likely in equilibrium between a monomeric, cytosolic and dimeric, membrane bound form [96]. Intriguingly, PD associated mutations in the ROC-COR domain were proposed to alter LRRK2 dimerization and cellular localisation [91,92]; however, the
detailed mechanisms as to how the GTPase and kinase domain reciprocally cross regulate activity remains elusive [76,86].

The most common LRRK2 mutation associated with PD, G2019S, is located in the kinase domain and causes a modest 2-fold increase in kinase activity and phosphorylation of substrates in vitro [77] and in vivo [97], while increasing the LRRK2G2019S autophosphorylation activity 4-fold [98]. The LRRK2R1441C mutation, located in the ROC domain, disrupts GTP hydrolysis, enhancing both substrate phosphorylation and autophosphorylation activity by approximately 3 to 4-fold [89,97,99]. These differences in kinase activity might explain the lifetime risk of PD in LRRK2 mutation carriers, with higher penetrance observed for LRRK2R1441C carriers [1], although with a later age of onset when compared with LRRK2G2019S carriers [1], illustrating that more complex mechanisms may be in action. In addition, while the impact of the LRRK2G2019S substitution is restricted to the kinase pocket of LRRK2, any alteration in the GTPase domain is likely to exert broader biochemical and cellular effects on protein function [90].

The majority of individuals with LRRK2 PD present with classical PD symptoms and exhibit variable Lewy body pathology upon post mortem examination [10,57]. Interestingly, all LRRK2 PD cases exhibit significant tau accumulation [57,58,100–102], a pathology observed in some idiopathic PD cases [103], particularly in PD with dementia [104]; however, this is not a diagnostic hallmark of PD upon autopsy [4,9]. Moreover, the tau gene MAPT is within a consistent idiopathic PD GWAS locus [24,103], illustrating its potential relevance in idiopathic PD. Lewy bodies and tau have a pleomorphic role in neurodegenerative disease pathology [105,106]. The former are pathognomonic for dementia with Lewy bodies [107], with α-synuclein found in glial cytoplasmic inclusions in Multiple System Atrophy (MSA) [108] and are found as a secondary protein aggregate pathology in up to half of Alzheimer’s disease (AD) cases [109]. Meanwhile, tau is a prominent player in multiple neurodegenerative conditions including AD [110], progressive supranuclear palsy (PSP) [111] and frontotemporal dementia (FTD) [112]; hence, study of LRRK2 with its associated tauopathy and Lewy body aggregation may be applicable to a range of neurodegenerative conditions.

LRRK2 is notable for exhibiting pleomorphic pathology in neurodegeneration and in the peripheral immune system [113]. In terms of neurodegeneration, variants in the LRRK2 locus have recently been identified through GWAS as candidates for increased survival in the tauopathy PSP [114]. Additionally, LRRK2 is highly expressed in many cell types of the immune system [115] and its expression is increased in the B cells, T cells and CD16+ monocytes of idiopathic PD patients, compared with the unaffected control population [116]. This suggests there may be a mechanistic role for LRRK2 in PD relevant inflammation. Notably, variants in LRRK2 have been observed to increase susceptibility to Mycobacterium leprae infection [117], the microbe causative of leprosy, characterised by peripheral neuron damage. Meanwhile, alternative variants in LRRK2 have been shown to increase the risk of Crohn’s disease [118], an inflammatory condition of the gastrointestinal tract. This further illustrates that studies of LRRK2 may shed additional insights into wider disease pathophysiology. In recent years, LRRK2 kinase hyperactivation has been implicated in idiopathic PD, while LRRK2 has remained a consistent candidate emerging from idiopathic PD GWAS [22,119–121] suggesting that LRRK2 functional modelling will provide insights into idiopathic disease, a current challenge in PD research.

LRRK2 as a therapeutic target

LRRK2 is a promising, druggable target for developing a disease modifying therapeutic for PD, with the potential to be applicable in some cases of idiopathic disease presented with LRRK2 hyperactivation [63]. However, upon the onset of diagnostic PD symptoms, disease pathology is already well established. Concurrent with the development of novel therapeutics, early biomarkers for PD and LRRK2 hyperactivation are under extensive investigation, with the aim to enable targeted pharmacological therapies early in disease pathogenesis or at a prodromal stage [122,123]. For over a decade, it has been known that LRRK2 inhibitors targeting kinase activity can protect against PD-associated phenotypes driven by LRRK2 phosphorylation, in in vitro and in vivo models [124]. Inhibitors have been under extensive development, and in pre-clinical models they have abated α-synuclein mediated neurodegeneration [125,126]. Currently, LRRK2 kinase inhibitors are undergoing early stage clinical trials for safety and efficacy (Clinical Trial ID:NCT03710707 [79], NCT04056689 [80]). Furthermore, splice-switching antisense oligonucleotides (ASOs) targeting LRRK2 have demonstrated that in human patient-derived cells and murine humanised models, LRRK2 levels can be stably reduced, leading to reduced LRRK2-mediated phosphorylation activity [127]. Reduced α-synuclein inclusions and dopaminergic neuron loss have been observed in the brain of LRRK2-ASO treated mice exposed to α-synuclein, while peripheral, off target effects of loss of LRRK2 expression were avoided through direct CNS injection of the ASO [128]. ASOs targeting LRRK2 are also entering early stage clinical trials (Clinical trial ID:NCT03976349 [119]), with promising potential. Indeed, ASOs are approved for clinical use in the treatment of
spinal muscular atrophy in over 40 countries [120], illustrating their relevance in neurodegenerative disease therapeutics.

The development of novel, disease modifying therapeutics for PD hinges upon the thorough understanding of perturbed pathways and the identification of druggable targets that arise, often elucidated through gene functional studies. Substantial progress has been made in utilising C. elegans as a simple in vivo model for PD genes and as a platform for high-throughput screening of chemical and genetic modifiers [21]; however, there is extensive room for further development and understanding.

The evolutionary conservation of LRRK2 in C. elegans

The ROCO proteins are conserved even in simple eukaryotes, such as the slime mould amoeba Dictoyostelium discoideum [121], in which they were first described. Humans have two LRRK paralogs, LRRK1 and 2, while invertebrate models, such as Drosophila melanogaster and C. elegans have only one, dLRK2 and LRK-1 respectively. It has been hypothesised that LRRK2 arose as a gene duplication event, following the protostome-deuterostome split [129,130]. Studies of evolutionary gene duplications have suggested that splits can lead to sub-functionalisation in which the ancestral gene functions are duplicated into two separate genes [131]. In the instance of LRRK2, if sub-functionalisation has occurred, it may have retained similar functions to LRK-1. However, the functional conservation extent between C. elegans LRK-1 and LRRK2 is not yet established. Here, we will discuss current models of LRK-1 function, in contrast with established models of LRRK2 function in order to evaluate its suitability as a model for LRRK2 in PD.

Protein sequence alignments between LRK-1 and LRRK2 demonstrate that many key residues mutated in LRRK2 PD, or synthetically mutated to ablate catalytic activity, are conserved in C. elegans LRK-1 [132,133], implicating potential functional conservation between LRK-1 and LRRK2 (Figure 4). PD associated mutation or enzymatic residue conservation is not illustrated between human LRRK2, when aligned with LRK1, and differential PPI networks of LRRK1 and 2 suggest divergent cellular function [134,135]. In terms of sequence identity, the extent of conservation between LRK-1, LRRK1 and LRRK2 are broadly similar. Between LRK-1 and LRRK1, there is a 20.9% amino acid identity (35.9% similarity), while between LRK-1 and LRRK2, there is a 20.3% identity (36.3% similarity) [65,136]. LRK1 and LRK2 phosphorylate distinct subsets of RAB proteins, downstream effectors of LRRK activity [137], and mutations of LRK1 lead to a rare bone condition, osteosclerotic metaphyseal dysplasia [138–140], also indicative of divergent functionality. Future modelling of key PD pathogenic LRRK2 mutations and variants in C. elegans LRK-1 (Figure 4) may shed light on the extent of functional conservation between C. elegans LRK-1 and mammalian LRK1 and LRRK2.

When contrasted with LRRK2 mammalian in vitro and in vivo model systems, functional studies of C. elegans LRK-1 suggest it is a promising candidate as a LRRK2 model, as extensively detailed in Figure 5 and throughout this review. Here, we will first discuss the role of LRK-1 deletion and humanised LRRK2 transgenic models, followed by insights gleaned from study of LRK-1. This will be succeeded by the C. elegans conservation of the RAB29/LRRK2 axis, retromer dysfunction and protein aggregation, pertinently tau and α-synuclein in modelling LRRK2-linked Parkinson’s pathogenesis, with potential implications for modelling the candidate genes of novel GWAS loci.

The relevance of LRK-1 deletion models for PD

Studies of LRRK2 function in C. elegans have often been limited to lrk-1 gene deletion, or transgenic overexpression of human LRRK2 on a wild-type nematode background [132,133,141–143]. Deletion models are useful in understanding physiological LRK-1 function, however in the context of understanding the biology of LRRK2 mutation driven PD, the modelling needs to be extended to the individual gene variants with proven, or possible pathogenicity. PD-linked mutations in LRRK2 have consistently been shown to act through a toxic gain of function mechanism, in which phosphorylation activity of LRRK2 is increased [78]. Human genetic studies have illustrated that there are individuals with heterozygous loss of function variants in LRRK2 [144], leading to an approximately 50% reduction in LRRK2 protein levels [144,145]. These individuals do not present with PD and have no significant health complications [145]. This suggests that in humans there could be compensatory mechanisms for LRRK2 function reduction, and that drug delivered kinase inhibition, or application of ASOs in therapeutics may not be deleterious. However, in pre-clinical rodent and non-human primate animal models, LRRK2 inhibitor treatment presented on-target side effects in the lung, showing abnormal accumulation of lysosomal related organelles known as lamellar bodies [146]. Encouragingly, this phenotype was reversible [146], and early stage clinical trials of LRRK2 inhibitors have so far showed safety and tolerability [79,80]. Pre-clinical in vitro models illustrate that LRRK2 inhibition does not significantly affect LRK1 phosphorylation activity, supporting their distinct structure and function [147]. In the context of C. elegans, deletion mutant and RNAi loss of function lrk-1 models would not provide an orthologous tool to
modelling the PD gain of function LRRK2 mutations. Furthermore, *C. elegans* lrk-1 deletion models do not show impaired dopaminergic phenotypes and behave similarly to wild-type [141], supporting the human genetics findings [145].

**Insights from transgenic expression of LRRK2 in *C. elegans***

Using humanised *C. elegans* models, through overexpressing human LRRK2 in wild-type and PD mutant form, it is possible to model gain of function mutation effects [76]. However, caution is needed when interpreting data, as little is known about the background phosphorylation activity and potential interplay, dimerization and functional redundancy of wild-type *C. elegans* LRK-1, when human LRRK2 is co-expressed. Adult *C. elegans* with a wildtype *lrk-1* background, expressing LRRK2<sup>2019S</sup> and LRRK2<sup>R1441C</sup> in the dopaminergic neurons, alongside a dopaminergic neuron specific GFP reporter, exhibit significantly reduced GFP fluorescence by day 3 of adulthood, indicative of dopaminergic neurodegeneration [148]. This has been replicated in further studies, illustrating that these models have a robust, PD associated phenotype, relevant to LRRK2 modelling [76,149]. Often, rodent models do not recapitulate key PD hallmarks in terms of neuropathology [150]; however, viral-mediated PD mutant LRRK2 overexpression induces dopaminergic neuron loss [151,152]. The development of PD relevant phenotypes and neuropathology in rodents occurs over several months, while *C. elegans* have an advantage in speed, sample size and exhibition of robust phenotypes within days.

Furthermore, *C. elegans* are highly amenable to environmental toxin assays and drug screens to evaluate the interplay with transgenic expression of human proteins of interest [153,154]. *C. elegans* strains overexpressing the PD associated LRRK2<sup>2019S</sup> and LRRK2<sup>R1441C</sup> mutant proteins in neurons show reduced survival in response to oxidative stress induced by the environmental toxins rotenone and paraquat, widely used in toxin-based models of PD [155], when compared with animals expressing wild-type LRRK2 [142,148]. However, these studies did not examine whether protection was kinase dependent, through LRRK2 inhibition, or expression of kinase inactive LRRK2. Notably, *C. elegans* overexpressing wildtype LRRK2 show enhanced survival to oxidative stress and increased lifespan.
compared with non-transgenic wild-type animals. This suggests a LRRK2-driven protective effect, while deletion, or RNAi silencing of lrk-1 in non-transgenic lines have shown a significantly reduced survival under these conditions [148,156]. Overexpression of LRK-1 is yet to be utilised in oxidative stress assay, so it is currently unknown whether this would have a similar effect to heterologous expression of LRRK2. These results suggests that PD mutant LRRK2 has a reduced efficacy in oxidative stress protection in C. elegans. However, the expression of these pathogenic LRRK2 variants in wildtype C. elegans background provides enhanced stress resistance compared with wild-type, non-transgenic C. elegans. This suggests that examination of the role of endogenous LRK-1 mutant proteins, with physiological expression levels, might provide better understanding of how these mutations impact survival of the organism, or the dopaminergic neurons. Nevertheless, this illustrates LRK-1s global role in oxidative stress survival, which may not be neuronal specific or restricted to neurons.

Additionally, the transgenic lines discussed above have been utilised as in vivo models to test early LRRK2 inhibitors LRRK2in1 and TTT-3002 [157,158]. Dopaminergic behavioural phenotypes and neurodegeneration observed in vehicle treated nematodes expressing LRRK2G2019S or LRRK2R1441C [76] are rescued following treatment with any of the two LRRK2 inhibitors [76]. However, the effect of LRRK2 inhibitors upon endogenous LRK-1 is unknown, and molecular readouts for LRK-1 phosphorylation activity remain to be identified. Similar effects in nematode behaviour, dopaminergic neurodegeneration and LRRK2 phosphorylation activity were demonstrated in a recent study utilising allosteric inhibition of LRRK2 kinase activity by vitamin B12 in LRRK2G2019S expressing lines [149], in support of the robust, relevant phenotypes and promise of C. elegans in pharmacological assays.

The use of transgenic human LRRK2 expressing C. elegans models have contributed to our understanding of LRRK2 function, while studies of LRK-1 suggest it may share functional conservation with LRRK2. Further characterisation and understanding of C. elegans LRK-1 function may shed further insight into LRRK2 mediated pathology from a novel model angle.

**LRRK2 and C. elegans LRK-1 functionality in vesicle trafficking, endocytosis and WNT signalling**

Data obtained upon transgenic expression of C. elegans LRK-1 generally supports the hypothesis that it may share some functional conservation with LRRK2. In 2007 C. elegans LRK-1 was suggested to have a role in regulating synaptic vesicle localisation to the dendrites of neurons, through modulating protein sorting in the Golgi in a kinase activity dependent manner [133], while deletion of LRK-1 leads to increased sensitivity to tunicamycin induced endoplasmic reticulum stress [132]. Accordingly, enrichment at Golgi and the regulation of intraneuronal protein sorting through this network has also been reported in studies of LRRK2 in rat cortical neuron cultures in vitro, and in Drosophila melanogaster and rodent models, in vivo [159]. Expression of C. elegans LRK-1K1726A and LRK-1G1877T mutant proteins in the C. elegans lrk-1 deletion mutant, (equivalent missense point mutations of the synthetic kinase ablation LRRK2G2019S and PD associated kinase hyperactive LRRK2I2020T, respectively) have demonstrated that kinase activity of LRK-1 is crucial to its function in determining polarised vesicle localisation in axons of C. elegans sensory neurons, suggesting shared conservation in enzymatic activity and functionality between LRK-1 and LRRK2 [133,160]. LRRK2 kinase activity has recently been shown to be essential in modulating axonal transport, with abnormal activation of kinesin in vitro and in vivo in PD LRRK2G2019S mutant models [161]. Interestingly, in the 2007 study of LRK-1, localisation of synaptic vesicle proteins was shown to depend on the C. elegans protein UNC-101, an orthologue of the clathrin adaptor protein AP-1 [160] involved in vesicle trafficking from the Golgi to endosome. Clathrin adaptor proteins are integral to vesicle transport processes, including clathrin-mediated endocytosis (CME), a process also regulated by LRRK2 [162]. Alterations to the CME process have been recognised in PD [163–165] and other neurodegenerative conditions [166,167], implicating potential functional overlap in the C. elegans model.

WNT/β-catenin signalling is an essential pathway in dopaminergic neurogenesis during development and also contributes to synapse formation and neuroprotection during ageing [168]. As PD is caused by the loss of dopaminergic neurons, the WNT/β-catenin pathway is of great interest in the development of disease modifying therapeutics targeting neurogenesis [168]. Importantly, LRRK2 plays key roles in the WNT signalling pathways [78,169–171]. LRRK2 modulates axonal development through inducing phosphorylation of the WNT receptor Frizzled3, a component of the planar cell polarity (PCP) pathway in mice [169], with both loss of function and kinase overactive LRRK2 mutants presenting axon guidance defects. Likewise, in C. elegans the WNT signalling pathways modulate neuronal development [172–174]. Interestingly, expression of the C. elegans LRK-1G1876S (the equivalent of human pathogenic LRRK2G2019S) in wild-type, or lrk-1 deletion mutant background, revealed significant defects in canal-associated neuron development [132]. Furthermore, in an RNAi screen targeting endogenous genes in wildtype C. elegans lines
overexpressing human LRRK2G2019S, endogenous nematode WNT signalling pathway components and axon guidance genes had the largest effect sizes in determining dopaminergic neuron survival [175]. Thus, this shared phenotype of impaired neuronal development and survival through WNT pathways between transgenic C. elegans LRK-1 and vertebrate LRRK2 models further strengthens the conserved roles of LRK-1 and LRRK2.

The shared interactome of LRRK2 and C. elegans LRK-1

Comparative study of LRK-1 and LRRK2 interactomes further supports functional conservation and it might provide another strategy to identify candidate pathways as novel therapeutic targets [71]. LRRK2 has been shown to bind the BAG2-HSC70 chaperone complex, acting as a chaperone for LRRK2 [176]. In C. elegans, UNC-23 and HSP-1, the orthologues of BAG2 and HSC70 respectively, interacts with LRK-1, highlighting existing conservation of protein interactions [176]. Further functional studies have illustrated that UNC-23 mediates Golgi localisation of LRK-1 in co-operation with HSP-1, and unc-23 deletion mutants phenocopy the defects in synaptic vesicle localisation [176], as seen in lrk-1 deletion mutants [132,133,176]. This suggests that UNC-23 and LRK-1 function together in synaptic vesicle localisation.

LRRK2 has an extensively characterised interactome; a stringent search through PINOT, a resource for obtaining quality controlled PPIs in humans and C. elegans [177], indicated 1440 interactor hits for LRRK2, replicated with multiple studies and methods (July 2021). In contrast, the LRK-1 interactome is poorly characterised, with only few interactors noted. Due to the existing conservation of interactions and of the molecular and cellular function between LRK-1 and LRRK2, C. elegans could provide an excellent tool to drive interactome-based functional studies. These could be investigated in the context of the ageing organism, including environmental and genetic PD risk factors, utilising the high-throughput nature of this model to assess the efficacy of genetic and chemical disease modifiers.

The role of Parkinson’s disease GWAS candidate risk gene RAB29 in LRRK2 and idiopathic PD

RAB proteins are a superfamily of small GTPases, with diverse regulatory roles in vesicle formation, trafficking and endosomal transport. A subset of these RABs are key effector substrates of LRRK2 phosphorylation [178]. RAB29, also known as RAB7L1, has been a consistent PD GWAS hit [24] and the RAB29 protein has been shown to act upstream of LRRK2 [179], while RAB3, RAB5, RAB8, RAB10, RAB12, RAB35 and RAB43 have been demonstrated to be downstream effector substrates regulated by LRRK2 phosphorylation [180]. RAB29 has been stratified through unbiased LRK-1 PPI arrays as a candidate risk gene, which may bridge the gap between familial LRRK2 and idiopathic PD [159,179,181]. Thus, our understanding of the mechanisms of both LRRK2 and idiopathic PD may be furthered by functional studies of RAB29.

RAB29 has been demonstrated to be a selective master regulator of LRRK2, acting upstream and leading to LRRK2 kinase recruitment, localisation and activation on the Golgi membranes, via binding of RAB29 to LRRK2s ankyrin repeat domain [179,182,183], with resultant increased LRRK2 kinase activity leading to changes in the trans-Golgi network morphology [184]. However, in another study RAB29 knockout had no impact on basal LRRK2 phosphorylation activity [185], suggesting a potentially more complex mechanism in LRRK2 modulation and PD pathogenesis. Furthermore, RAB29 is also a substrate of LRRK2 in human HEK293 cells; LRRK2 with kinase overactive PD mutations LRRK2R1441C, LRRK2Y1699C and LRRK2G2019S present a 4-fold increase of RAB29 mediated phosphorylation of RAB29 [178], suggesting interdependent regulation between these two proteins. Other key substrates of LRRK2 are RAB8A and RAB10, with RAB8A shown to accumulate at the trans-Golgi network following RAB29 mediated LRRK2 recruitment [182]. Furthermore, upon stress induced lysosomal enlargement, LRRK2 is targeted to the lysosomal membranes via RAB29 [183]. This leads to an accumulation of RAB8A and RAB10, which attenuates the enlargement of lysosomes, essential for maintaining their integrity and function [183]. Thus, RAB29 is integral to LRRK2 biology and function, further highlighting the need to develop our understanding of the pathways in a range of models.

The conservation between RAB29 and C. elegans orthologue, GLO-1

C. elegans has an orthologue for RAB29, glo-1, which shows conservation in its function in the endolysosomal transport pathway [186]. A coding variant RAB29G1157R has been detected in an idiopathic PD patient [187], however its pathogenicity, as well as its mechanism of action is unconfirmed. This variant position is conserved in C. elegans GLO-1 and is located within the G5 loop, involved in binding of small G-proteins to nucleotides [71,188]. Important, C. elegans GLO-1 has been shown to act upstream of C. elegans LRK-1 [189], congruent with studies of human LRRK2, further suggesting it may be relevant for further functional modelling of RAB29. GLO-1 is also the C. elegans
orthologue for the closely related human RAB32 and RAB38, and it is most similar to these proteins in terms of protein sequence identity [29]. GLO-1 shares 45.9% and 46.1% sequence identity with RAB32 and RAB38 respectively, while with RAB29 it shares a 40.7% identity [65,136]. Functional studies of GLO-1 have demonstrated that it shares conservation with all three RAB proteins to varying extents. In vivo model organisms do not always show exact orthologue conservation with the human gene of interest. For example, mouse models display significant differences in biology and biochemistry of LRRK2 when compared with human [150]. Despite this, much useful information has been gleaned through functional modelling of LRRK2 in mice [128,151,152], which can be contrasted or supported by consistent findings in alternate in vivo, in vitro and in silico models, along with findings reported in studies of PD patients. Thus, C. elegans GLO-1, when taken in conjunction with findings in other models, will be a useful model for further understanding RAB29 function, along with shedding insight into its close counterparts RAB32 and RAB38.

GLO-1 may not just be a potential functional model with relevance to PD, as RAB29, RAB32 and RAB38 have been highlighted as genes of interest in various neurodegenerative conditions. Functional studies of RAB29 in the presence of C9orf72 hexanucleotide repeat [190], causative of amyotrophic lateral sclerosis with FTD (ALS-FTD), have illustrated its role in vesicle trafficking [191]. Additionally, RAB38 has been identified as a significant GWAS hit in a behavioural variant subtype of FTD [192], while RAB32 has been associated with ER stress and mitochondrial dysfunction in multiple sclerosis [193]. This illustrates that this small sub-group of RABs may play an important role in the maintenance of neuronal health and an in vivo reductionist model of their functions focusing on GLO-1 may be applicable to further research areas.

The LRK-1/GLO-1 interplay in C. elegans
Congruent with the human RAB29/LRRK2 axis, in C. elegans both endogenous LRK-1 and neuronally expressed human LRRK2 on a lrk-1 deletion background have been shown to act downstream from GLO-1 in axon termination [189]. Notably, key residues of RAB29, routinely utilised to synthetically ablate or constitutively activate its GTPase function in vitro [190], are conserved in C. elegans GLO-1. On the other hand, key LRRK2 phosphorylation target sites T71 and S72 of RAB29 [194] are not conserved. GLO-1 and LRK-1/LRRK2 converge to regulate axonal morphology, highlighting their importance in the nematode central nervous system, and like RAB29 and LRRK2, they have lysosomal roles [189]. In motor neuron axons, GLO-1 and LRK-1 act to modulate endo-lysosomal trafficking or endo-lysosomal maturation, suggesting similar functions to their human counterparts [189]. Transgenic expression of PD mutant LRRK2G2019S or LRRK2R1441C in lrk-1 deletion mutants efficiently suppresses the axonal abnormality phenotype exhibited in lrk-1 or glo-1 deletion mutants [189], suggesting high functional conservation. However, the effect of human RAB29/32/38 expression in glo-1 deletion mutant background was not investigated, nor was the Golgi localisation of both proteins [189]. Furthermore, the effect or presence of LRK-1/LRRK2 mediated phosphorylation of GLO-1 was not investigated [189], as robust phosphorylation readouts have not been developed for PD relevant orthologues in C. elegans. This highlights the need for additional studies to further assess the LRK-1/GLO-1 mechanistic conservation with the comparatively better understood LRRK2/RAB29 interplay.

The relevance of RAB32 and RAB38 in understanding RAB29 and LRRK2 function
Functional studies of human RAB32 and RAB38 implicate some shared pathways with RAB29, augmenting the relevance of glo-1 for further study. RAB32 and RAB38 have been demonstrated to act co-operatively to regulate lysosomal biogenesis and modulation of lysosome-related organelles (LROs) [195]. In C. elegans, GLO-1 modulates the biogenesis of LROs, which are intracellular compartments for storage, sharing some characteristics but coexistent with conventional lysosomes [186,196]. Furthermore, human RAB32 and RAB38 co-ordinate lysosomal biogenesis through the clathrin adaptor protein AP-3 [195], which is a known effector substrate of LRRK2, acting downstream from RAB29 [189]. Similarly, studies of GLO-1 have identified modulation of LRO biogenesis through APB-3, the C. elegans orthologue of AP-3, via C. elegans LRK-1 [197], mirroring the human pathway [189]. Additionally, nematodes with deletion of glo-1 or apb-3, or double deletion mutants of these genes, show decreased LRO biogenesis [189], suggesting convergent biology and importance in this function, as shared in the RAB32 and RAB38 interplay with AP-3. These mutual processes, pathways and interactors suggest that GLO-1 shares high functional conservation with RAB32 and RAB38.

Similarly to RAB29, RAB32 and RAB38 also share convergent biology with LRRK2, although their mechanisms of interaction may differ. RAB32 and RAB38 have been shown to mediate phagosome restriction of intracellular
pathogens, notably Mycobacterium leprae, the causative agent of leprosy [198]. Interestingly, single-nucleotide polymorphisms (SNPs) in LRRK2 have been identified through GWAS as predisposing towards leprosy [117], and a polymorphism in RAB32 [199] has also been associated with disease susceptibility, implicating potential shared pathways in the immune response between LRRK2 and RAB32 and RAB38. It is currently unclear whether these immune pathways also contribute to PD pathogenesis [200]. However, it has been hypothesised that PD associated mutations in LRRK2, prevalent in multiple human populations [201], may confer greater immunity to selected infectious diseases. This may have led to a balanced selection of LRRK2 PD mutations, resulting in antagonistic pleiotropy, with potential advantageous roles of mutation in immunity, but increased risk of PD development in later life [113,202].

LRRK2 physically interacts with RAB32 and RAB38 through its armadillo domain [203], convergent with the LRK-1 and GLO-1 interaction [189]. Furthermore, RAB32 and RAB38 bind to sortin-nexin 6 (SNX-6), a transient subunit of the retromer complex, affecting retromer dependent Golgi trafficking [204]. Recent studies have demonstrated that LRRK2, bound to trans-Golgi localised RAB29, interacts with the GARP complex, stabilising syntaxin-6 and promoting retrograde transport to the trans-Golgi network in a kinase dependent manner [205]. Importantly, syntaxin-6 and all GARP subunits are conserved in C. elegans and RNAi knockdown of GARP subunits in C. elegans expressing human LRRK2G2019S in the dopaminergic neurons [141] induces dopaminergic neurodegeneration [205]. This proposed functional convergence of RAB29, RAB32 and RAB38 at the trans-Golgi network, with influences on trafficking and LRRK2 interaction suggest that GLO-1 may have retained similar functions of its three evolved human orthologues and may therefore be useful in gaining further mechanistic insight into the events linking these proteins to neurodegeneration.

Convergence of LRRK2 with VPS35 linked Mendelian Parkinson’s disease

A mutation in Vacuolar Protein Sorting 35, VPS35D620N, was identified in 2011 in a small number of families with late onset, autosomal dominant PD, showing similar symptomatic presentation to idiopathic PD [206–208]. VPS35 is an integral subunit of the retromer complex, implicated in retrograde transport between the endosomes and the trans-Golgi network [209]. VPS35 and its link with the retromer was first described in the unicellular Saccharomyces cerevisiae [209–211]. C. elegans has a well conserved, direct VPS35 orthologue, vps-35 [212]. Interestingly, VPS35D620N has been shown to enhance LRRK2 kinase activity 6-fold in vitro, in CRISPR engineered murine fibroblasts and neutrophils isolated from PD patients carrying VPS35D620N [99]. This suggests an interplay between LRRK2 and the retromer in PD, a plausible hypothesis for the molecular mechanism of VPS35D620N PD, further highlighting the roles of LRRK2 and the endosomal network in neurodegeneration.

Studies conducted in C. elegans thus far have demonstrated that VPS-35 and the retromer have a role in modulating WNT signalling, determining neuronal migration during development [172,173,213–215]. The role of VPS35 in WNT signalling is conserved in other invertebrate models, such as, but also in mammals as observed in cell culture studies [215,216], suggesting maintained functional conservation through evolution. Recently, heterozygous VPS35D620N mouse models have been reported to display WNT/β-catenin signalling dysfunction [217]. The potential pathogenic perturbation of the WNT signalling pathway [217], converging with its impairments illustrated in the LRRK2 PD models [78], implicates WNT signalling as a core process with relevance to PD pathogenesis. In C. elegans, VPS-35 has been implicated in trafficking of the nematode orthologue of the excitatory AMPA glutamate receptor, GLR-1. Deletion of vps-35 leads to a significant reduction in the number of GLR-1 puncta on the post-synaptic surface of ventral nervous cord dendrites and suggests a role for the retromer in GLR-1 recycling [218]. Coherently, in iPSC neuronal cultures derived from people with VPS35D620N PD, APMA receptor trafficking was dysregulated and receptors were mislocalised [219]. This shared role between C. elegans VPS-35 and its human orthologue suggest retained functional conservation through evolution.

The role of retromer dysfunction in tauopathies

Similarly to LRRK2, VPS35 has been associated with tauopathies in in vivo and in vitro modelling [220,221]. It is currently unclear whether individuals with VPS35D620N PD exhibit typical α-synuclein pathology, as due to the rarity of mutations in this gene autopsy studies to date have been very limited [222]. In 2008, a post mortem study was undertaken with one individual from a Swiss family with multi-generational PD, who was later identified as a VPS35D620N carrier [8]. Key PD relevant brain areas were not analysed, but α-synuclein pathology was not observed [8]. Hence, additional studies to obtain further insight into α-synuclein and tau pathology are required. In vivo murine models with VPS35D620N endogenously knocked in exhibit progressive neurodegeneration driven by tauopathy [220], while
retromer has been shown to modulate the lysosomal clearance of tau in vitro [221]. The evidence of VPS35D620N resulting in enhanced LRRK2 kinase activity [99] further suggests that tauopathy could be present in VPS35D620N PD, as tauopathy is a hallmark of LRRK2 PD [102]. Additionally, kinase overactive LRRK2G2019S has been demonstrated to enhance neuronal transmission of tau in mouse models [152]. Tau, a key protein in AD and FTD, is a PD GWAS locus and has been observed in approximately 50% of PD patients post-mortem, illustrating the relevance of functional study of LRRK2 for further mechanistic insights potentially applicable to a range of neurodegenerative conditions.

Like tauopathies, retromer dysfunction has been implicated in multiple neurodegenerative conditions, suggesting potential common perturbed pathways and an essential role in neuronal function. In AD autopsy studies, microarrays have illustrated that retromer is depleted in the hippocampus, within the dentate gyrus and entorhinal cortex, a region in which AD pathology is initiated [223]. Further mechanistic studies have shown that retromer facilitates the trafficking of amyloid precursor protein (APP) through sortilin binding within the retromer, thus retromer deficiency leads to APP accumulation and cleavage to pathogenic β-amyloid [224], a driver of AD pathogenesis [225]. Thus, further study of the retromer in the well-conserved C. elegans model may shed further insight into multiple pathologies.

Modelling tauopathies in C. elegans

C. elegans have a tau-like orthologue, pti-1 [226,227] and multiple evidence suggests that this protein may cover essential roles in maintaining neuronal integrity through the lifespan when expressed at basal levels [228]. Loss of pti-1 is not rescued by expression of human tau isoforms [228], suggesting potentially limited functional conservation between pti-1 and human tau. Multiple studies have used transgenic expression of human tau isoforms, investigating the impact of overexpression of wildtype or pathogenic mutant tau in C. elegans. Overexpression of wild-type tau in C. elegans, or neuronal expression of A152T mutant tau [229], a risk factor for FTD, PSP and atypical tauopathies [112,230] have been demonstrated to induce neuronal dysfunction [231]. Expression of tauA152T in C. elegans leads to impaired associative memory, compared with animals expressing wildtype tau [232], and this may be explained by differential impacts on retrograde axonal transport [232], of which the retromer is a central component. The emergence of tau as a contributor to LRRK2 and VPS35 linked PD, the emerging aetiological overlap with the tauopathies and the existence of ready to use tauopathy models in C. elegans, provides further opportunities for functional studies and modifier screens of tau pathology, with impacts on multiple neurodegenerative conditions.

Modelling α-synuclein pathology in C. elegans to dissect PD gene function

The first gene to be directly implicated in inherited PD was the SNCA gene on chromosome 4 [233]. In 1997, a missense coding variant in SNCA (A53T) was found to segregate with PD and dementia in a large family of Greek and Italian origin, the Contursi kindred [233]. Soon after, α-synuclein, the protein product of SNCA, was identified as the major constituent of Lewy bodies [166]. The aggregation propensity of α-synuclein and its involvement in neurodegenerative diseases had already been reported, albeit without being recognised as α-synuclein, as it had previously been associated with the non-amyloid component of plaques in AD patients [234], who frequently develop Lewy bodies [109,235]. Since 1997, six SNCA missense mutations, as well as gene duplications and triplications have been linked to dominantly inherited PD and dementia, suggesting that an increase not only in the aggregation tendency but also in the expression level of α-synuclein can induce toxicity [236]. More recently, the advent of GWAS revealed that the SNCA locus is among the major determinants of PD predisposition in the general population [237], with variability in common risk loci contributing to the polygenic risk of lifetime PD development [16,24,107,238,239]. These genetic findings have driven functional research, supported by the evidence that SNCA, as many others, is a pleiotropic PD gene and that PD follows an oligogenic pattern of inheritance [18,240]. A key unanswered question therefore is, to what extent interplay between α-synuclein and other PD proteins contribute to the aetiology of PD [241–245].

C. elegans do not possess an orthologue of SNCA; however, multiple C. elegans models have been generated expressing wild-type or mutant human SNCA as a transgene, in muscles, neurons or dopaminergic neurons [246,247]. These have been illustrated to recapitulate PD hallmarks of dopaminergic neurodegeneration [155,246,247] and have been employed to study a diverse range of PD relevant pathways, shedding insights into PD pathology. These studies have been discussed in depth in a recent comprehensive review, by Gaeta, Caldwell and Caldwell [248], therefore they will not be extensively covered here. RNAi screens, utilising α-synuclein overexpressing C. elegans models, have
demonstrated that multiple PD relevant genes, such as orthologues of PINK-1, PARKIN, ATP13A2 and DJ-1, identified in Mendelian familial studies are modifiers of α-synuclein pathology [249]. This suggests promising pathway conservation, illustrating the great potential to dissect the mechanisms of PD relevant genes, in conjunction with transgenically expressed α-synuclein in C. elegans.

The interplay of LRRK2/LRK-1 in α-synuclein transgenic models

Many pathways linking α-synuclein and LRRK2 have been suggested, including cytoskeletal dynamics, ER/Golgi transport, mitochondrial homeostasis and functionality of the degradative systems, leading to the hypothesis that the use of LRRK2 inhibitors might be beneficial in the treatment of synuclein pathology [250,251]. Lack or inhibition of LRRK2 kinase activity or LRRK2 deletion can mitigate neurodegeneration observed in rats after transduction of human α-synuclein via adeno-associated viral vectors (AAVs) [125,126,252]. Indeed, AAVs, together with lentiviral vectors, have been extensively exploited to deliver wild-type and mutant human α-synuclein to the substantia nigra of rodents and primates, where they lead to Lewy body formation and neurodegeneration. Conversely, overexpression of the wild-type or mutant human α-synuclein in rodents does not correlate with pathological aggregate formation and degeneration of dopaminergic neurons in the substantia nigra [253]. However, expression of human α-synuclein in the invertebrate models D. melanogaster and C. elegans recapitulates the major PD hallmarks such as impaired dopaminergic behaviour and neurodegeneration despite the lack of an orthologue [179,244].

Similar studies of α-synuclein propagation with regard to LRRK2 have been undertaken in vivo in rodent models and in vitro human derived SH-SY5Y cultures, and contrasted with C. elegans LRK-1 [252]. Interestingly, lrk-1 deletion mutant C. elegans shows reduced aggregation of α-synuclein, expressed in the muscle [252]. In the same study, this phenotype was recapitulated in the brain of LRRK2 knockout rats, injected with AAV vectors of recombinant human α-synuclein. These animals showed significantly reduced number of axons immunoreactive for α-synuclein at 12 weeks [252], consistent with LRRK2 inhibitor studies [125,126]. In a concurrent in vitro human SH-SY5Y culture study, this phenotype was determined as kinase activity dependent, with LRRK2G2019S enhancing α-synuclein propagation, through RAB35 phosphorylation, a mechanism demonstrated to be conserved in C. elegans [252]. Expression of a constitutively active RAB35 in the lrk-1 deletion mutant reversed the phenotype of reduced α-synuclein aggregation [252], further illustrating that key mechanisms and pathways in PD pathogenesis are readily modelled in C. elegans, despite the simplicity and evolutionary differences of the system.

However, deletion models of PD orthologues, when used in conjunction with α-synuclein expression still need to be approached with caution. A study developing a C. elegans model for neuron-neuron propagation of α-synuclein in vivo demonstrated that RNAi silencing of PD orthologue genes, including lrk-1, pdr-1, pink-1, vps-35, resulted in increased α-synuclein propagation between neurons [254]. Furthermore, more complex mechanisms may be at play, as lrk-1 expression at the mRNA level has been shown to significantly increase in nematodes expressing α-synuclein in the muscle in the presence of the apoptosis inducer wedelolactone [255] and the flavonoid tambulin [256]. Both of these have been demonstrated to reduce α-synuclein aggregation in C. elegans muscles. Dysregulation of LRRK2 mRNA expression has been described in post-mortem studies of individuals with idiopathic and LRRK2G2019S PD [257]. However, these convergences and inconsistencies in C. elegans, with regards to the α-synuclein/LRRK2 interplay, further highlights the need to develop more precise genetic models of LRRK2 pathology in C. elegans, rather than depending solely on deletion and RNAi silencing studies.

LRRK2 and beyond: The potential of C. elegans for functional modelling of Parkinson’s disease GWAS candidate genes

The past two decades have witnessed a seismic change in our understanding of the genetic contribution to the aetiology of PD, culminating most recently in the 2019 meta-analysis of PD GWAS, identifying 90 risk loci for PD, that account for up to 36% of PD heritability [24]. In Ortholist2, a database mapping human genes to their C. elegans orthologues [29], 64 of the identified genes have direct orthologues in C. elegans, detailed in Figure 6. Considering the increasing speed in dissecting the genetic component of PD and the requirement for rapid and robust functional validation, new models are now required to introduce multiple mutations in a single background and study their interplay. Such a scenario is difficult to achieve in rodents, while C. elegans possess the optimal feasibility in terms of genetic manipulation, for the generation of oligogenic models, along with RNAi and chemical modulator screening to investigate the impact of genetic and environmental factors. Genome-wide RNAi screens are powerful, but could miss many potential modifiers, with subtle impairments that occur only in specific conditions. Thus, combined risk screens might constitute a novel era in PD research, for which a simple functional model is needed.
Figure 6. The potential for functional modelling PD GWAS loci in *C. elegans*

The most recent PD GWAS meta-analysis by Nalls et al [24] highlighted 90 genome-wide significant risk signals at 78 genomic regions, implicated in idiopathic PD. Search of the *C. elegans* orthologues of the nearest, or most relevant candidate genes suggested by the IPDGC GWAS locus browser [240], using Ortholist2 [29], demonstrated that 64 of the listed candidate risk genes have orthologues in *C. elegans*, yet to be characterised in the context of PD modelling.

As extensively detailed in this review, *C. elegans* orthologues of Mendelian PD genes such as *lrk-1* and *vps-35* show promising functional conservation with their human counterparts *LRRK2* and *VPS35*, when contrasted with a diverse range of *in vitro* and *in vivo* models. It is clear that in many model systems, *LRRK2* is a key player in PD pathway disruption and may further bridge the gap in our understanding of Mendelian to idiopathic PD. GWAS risk genes, such as *RAB29* (*glo-1* in *C. elegans*), also show great promise for further functional modelling in *C. elegans*. This opens the possibility of developing new nematode models to further understand the functionality of novel candidate genes, rapidly emerging through the availability of vast genetic data. The development of CRISPR/Cas9 technologies has enabled the rapid generation of knockin point mutations in *C. elegans* orthologues of human genes [56,258], although this approach is not yet as widely used as deletion, RNAi silencing and transgenic expression of PD-relevant genes [20,55,143,259,260]. Endogenous CRISPR/Cas9 engineered mutations enables precise modelling...
of human genetic variants that might pose as risk for developing PD [261]. As C. elegans is one of the easiest and cheapest multicellular eukaryotic organism to apply precise genome editing to, the choice of this simple nematode for studying PD biology provides fast, cheap in vivo modelling with great translational potential [21,29,51], as discussed throughout this review. C. elegans functional studies of other Mendelian PD genes and their orthologues, including PINK1, PARKIN, ATP13A2 and DJ-1, or PD risk genes, such as GBA1, have proven the strength of this invertebrate model, highlighting highly conserved functions of these genes and proteins in cellular pathways disrupted in PD, including mitophagy, lysosomal degradation and α-synuclein pathology [49,132,175,262–270]. Complex functional interaction of all of these PD proteins have been described in PD patient samples and in animal models, which supports the idea that LRRK2 is a master regulator of cellular trafficking and quality control pathways, maintaining a cross-talk of a multitude of cellular processes and reflects on the high complexity of Parkinson’s disease pathology [13,271–274]. Developing oligogenic C. elegans models, replicating the human genetic changes and evaluating cross-talk of various cellular pathways in PD, will help in enabling the future development of novel, disease modifying therapeutics.

Competing Interests
The authors declare that there are no competing interests associated with the manuscript.

Funding
This research was funded by grants from Parkinson’s UK [grant numbers H-1702 and G-2008]; the Medical Research Council [grant number MR/Q026004/1]; Michael J Fox Foundation [grant number 18285]; Aligning Science Against Parkinson’s consortium [grant number ASAP-0478]. R.J.C is funded by Parkinson’s UK PhD Studentship [grant number H-1702].

Open Access
Open access for this article was enabled by the participation of University of Reading in an all-inclusive Read & Publish pilot with Portland Press and the Biochemical Society under a transformative agreement with JISC.

Author Contribution
R.J.C contributed to the manuscript preparation, writing, figures and background research, with additions from S.C. E.K., P.A.L. and S.C. all contributed to the concept, background research, figures, editing and revisions of the manuscript. E.K., P.A.L., S.C. and R.J.C. all made intellectual contributions, edits and approvals to the manuscript for publication.

Abbreviations
APP, amyloid precursor protein; ASO, antisense oligonucleotide; CME, clathrin-mediated endocytosis; PD, Parkinson’s disease; PPI, protein–protein interaction.

References
1 Trinh, J., Guella, I. and Farrer, M.J. (2014) Disease penetrance of late-onset parkinsonism: a meta-analysis. JAMA Neurol. 71, 1535–1539, https://doi.org/10.1001/jamaneurol.2014.1909
2 Postuma, R.B., Berg, D., Stern, M., Poewe, W., Oertel, W. et al. (2015) MDS clinical diagnostic criteria for Parkinson's disease. Mov. Disord. 30, 1591–1601, https://doi.org/10.1002/mds.26424
3 Dickson, D.W., Braak, H., Duda, J.E., Duyskaerts, C., Gasser, T., Halliday, G.M. et al. (2009) Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet Neurol. 8, 1150–1157, https://doi.org/10.1016/S1474-4422(09)70238-8
4 Ali, K. and Morris, H.R. (2015) Parkinson’s disease: chameleons and mimics. Pract. Neurol. 15, 14–25, https://doi.org/10.1136/practneurol-2014-000849
5 Schrag, A., Horsfall, L., Walters, K., Noyce, A. and Petersen, I. (2015) Prediagnostic presentations of Parkinson’s disease in primary care: A case-control study. Lancet Neurol. 14, 57–64, https://doi.org/10.1016/S1474-4422(14)70287-X
6 Muller, T., Kuhn, W. and Przuntek, H. (1997) Non-motor symptoms of Parkinson disease. Significant impact on quality of life–using possible treatments. Fortschr. Med. 115, 45–48
7 Wu, Y.H., Lee, W.J., Chen, Y.H., Chang, M.H. and Lin, C.H. (2016) Premotor symptoms as predictors of outcome in Parkinson’s disease: a case-control study. Plos ONE 11, 17, https://doi.org/10.1371/journal.pone.0161271
8 Wider, C., Skipper, L., Solida, A., Brown, L., Farrer, M., Dickson, D. et al. (2008) Autosomal dominant dopa-responsive parkinsonism in a multigenerational Swiss family. Park Relat. Disord. 14, 465–470, https://doi.org/10.1016/j.parkreldis.2007.11.013
9 Braak, H., Del, K., Rüb, U., de Vos, R.A.L., Jansen, E.N.H. and Braak, E. (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol. Aging 24, 197–211, https://doi.org/10.1016/S0197-4580(02)00065-9
10 Marder, K., Wang, Y., Alcalay, R.N., Mejia-Santana, H., Tang, M.X., Lee, A. et al. (2015) Age-specific penetrance of LRRK2 G2019S in the Michael J. Fox Ashkenazi Jewish LRRK2 Consortium. Neurology 85, 89–95, https://doi.org/10.1212/WNL.0000000000001708
Bioscience Reports (2021) 41 BSR20203672
https://doi.org/10.1042/BSR20203672

11 Braak, H., Rüb, U., Gai, W.P. and Del Tredici, K. (2003) Idiopathic Parkinson’s disease: Possible routes by which vulnerable neuronal types may be subject to neuroinvasion by an unknown pathogen. J. Neural Transm. 110, 517–536, https://doi.org/10.1007/s00702-002-0808-2

12 Ma, C., Liu, Y., Neumann, S. and Gao, X. (2017) Nicotine from cigarette smoking and diet and Parkinson’s disease: a review. Transl. Neurodegener 6, 1–7, https://doi.org/10.1186/s40035-017-0090-8

13 Hernandez, D.G., Reed, X. and Singleton, A.B. (2016) Genetics in Parkinson’s disease: Mendelian versus non-Mendelian inheritance. J. Neurochem. 139, 59–74, https://doi.org/10.1111/jnc.13593

14 Struhal, W., Presslauer, S., Spießberger, S., Zimpich, A., Auff, E., Bruecke, T. et al. (2014) VPS35 Parkinson’s disease phenotype resembles the sporadic disease. J. Neural Transm. 121, 755–759, https://doi.org/10.1007/s00702-014-1179-1

15 Li, Y., Ikeda, A., Yoshino, H., Oyama, G., Kitani, M., Daida, K. et al. (2020) Clinical characterization of patients with leucine-rich repeat kinase 2 genetic variants in Japan. J. Hum. Genet. 65, 771–781, https://doi.org/10.1038/s10038-020-0772-4

16 Bandres-Ciga, S., Saiz-Almenar, S., Bonet-Ponce, L., Billingsley, K., Vitale, D., Blauwendraat, C. et al. (2019) The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson’s disease. Mov. Disord. 1–9, https://doi.org/10.1002/mds.27614

17 Robak, L.A., Jensen, I.E., van Rooij, J., Utterlinden, A.G., Kraaij, R., Jankovic, J. et al. (2017) Excessive burden of lysosomal storage disorder gene variants in Parkinson’s disease. Brain 140, 3191–3203, https://doi.org/10.1093/brain/awx285

18 Lubbe, S.J., Escott-Price, V., Gibbs, J.R., Nalls, M.A., Bras, J., Price, T.R. et al. (2016) Additional rare variant analysis in Parkinson’s disease cases with and without known pathogenic mutations: evidence for oligogenic inheritance. Assoc. Stud. Aut. 25, 5483–5489, https://doi.org/10.1093/hmg/ddw348

19 Keogh, M.J., Wei, W., Aryaman, J., Wilson, I., Talbot, K., Turner, M.R. et al. (2018) Oligogenic genetic variation of neurodegenerative disease genes in 980 postmortem human brains. Neurosci. Neurosurg. Psychiatry 89, 813–816, https://doi.org/10.1116/jjp-2017-317234

20 Caldwell, K.A., Willicott, C.W. and Caldwell, G.A. (2020) Modeling neurodegeneration in Caenorhabditis elegans. Dis. Model. Mech. 13, 1–15, https://doi.org/10.1242/dmm.046110

21 Cooper, J.F. and Van Raamsdonk, J.M. (2018) Modeling Parkinson’s disease in C. elegans. J. Parkinsons Dis. 8, 17–32, https://doi.org/10.3232/JPD-171258

22 Blauwendraat, C., Nalls, M.A. and Singleton, A.B. (2020) The genetic architecture of Parkinson’s disease. Lancet Neurol. 19, 170–178, https://doi.org/10.1016/S1474-4422(19)30287-X

23 Fung, H.C., Scholz, S., Matarin, M., Simon-Sanchez, S., Hernandez, D., Britton, A. et al. (2006) Genome-wide genotyping in Parkinson’s disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol. 5, 911–916, https://doi.org/10.1016/S1474-4422(06)70578-6

24 Nalls, M.A., Blauwendraat, C., Vallerga, C.L., Heibronn, K., Bandres-Ciga, S., Chang, D. et al. (2019) Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 18, 1091–1102, https://doi.org/10.1016/S1474-4422(19)30320-5

25 Smolders, S. and Van Broeckhoven, C. (2020) Genetic perspective on the synergistic connection between vesicular transport, lysosomal and mitochondrial pathways associated with Parkinson’s disease pathogenesis. Acta Neuropathol. Commun. 8, 1–28, https://doi.org/10.1186/s40478-020-00935-4

26 Liu, Z.H., Guo, J.F., Li, K., Wang, Y.Q., Kang, J.F., Wei, Y. et al. (2015) Analysis of several loci from genome-wide association studies in Parkinson’s disease in mainland China. Neurosci. Lett. 587, 68–71, https://doi.org/10.1016/j.neulet.2014.12.027

27 Griffin, E.F., Caldwell, K.A. and Caldwell, G.A. (2017) Genetic and Pharmacological Discovery for Alzheimer’s Disease Using Caenorhabditis elegans. ACS Chem. Neurosci. 8, 2596–2600, https://doi.org/10.1021/acschemneuro.7b00361

28 Sandhoff, C.A., Hoppe, S.O., Tittelmeier, J. and Nussbaum-Krammer, C. (2020) C. Elegans models to study the propagation of prions and prion-like proteins. Biomolecules 10, 1–23, https://doi.org/10.3390/biom10081188

29 Kim, W., Underwood, R.S., Greenwald, I. and Shaye, D.D. (2018) Ortholist 2: A new comparative genomic analysis of human and caenorhabditis elegans genes. Genetics 210, 445–461, https://doi.org/10.1534/genetics.118.310307

30 Bargmann, C.I. (1998) Neurobiology of the Caenorhabditis elegans genome. Science (80-) 282, 2028–2033, https://doi.org/10.1126/science.282.5396.2028

31 Equine, C.E.S., Iology, T.O.B. and The C. Consortium S. (1998) Genome sequence of the nematode C. elegans: A platform for investigating biology. Science (80-) 282, 2012–2018, https://doi.org/10.1126/science.282.5396.2012

32 Walther, D.M., Kasturi, P., Zheng, M., Pinkert, S., Vecchi, G., Ciryam, P. et al. (2015) Widespread proteome remodeling and aggregation in aging C. elegans. Cell 161, 919–932, https://doi.org/10.1016/j.cell.2015.03.032

33 Azulay, A., Itskovits, E. and Zaslaver, A. (2016) The C. elegans Connectome Consists of Homogenous Circuits with Defined Functional Roles. PLoS Comput. Biol. 12, 1–16, https://doi.org/10.1371/journal.pcbi.1005021

34 Cook, S.J., Jarrell, T.A., Britton, C.A., Wang, Y., Bloniarz, A.E., Yakovlev, M.A. et al. (2019) Whole-animal connectomes of both Caenorhabditis elegans sexes. Nature 571, 63–71, https://doi.org/10.1038/s41586-019-1352-7

35 Maulik, M., Mitra, S., Buit-Ito, A., Taylor, B.E. and Vanyo, E.M. (2017) Behavioral phenotyping and pathological indicators of Parkinson’s disease in C. elegans models. Front. Genet. 8, 1–21, https://doi.org/10.3389/fgene.2017.00077

36 Smith, L.L., Ryde, I.T., Hartman, J.H., Romers, R.F., Markovich, Z. and Meyer, J.N. (2019) Strengths and limitations of morphological and behavioral analyses in detecting dopaminergic deficiency in Caenorhabditis elegans. Neurotoxicology 74, 209–220, https://doi.org/10.1016/j.neuro.2019.07.002

37 Chase, D.L. and Koele, M.R. (2007) Biogenic amine neurotransmitters in C. elegans. WormBook 1–15, https://doi.org/10.1895/wormbook.1.132.1

38 Segalat, L., Elkes, D.A. and Kaplan, J.M. (1995) Modulation of serotonin-controlled behaviors by Go in Caenorhabditis elegans. Science (80-) 267, 1648–1651, https://doi.org/10.1126/science.7886454
126 Daher, J.P.L., Abdelmotilib, H.A., Hu, X., Volpicelli-Daley, L.A., Moeble, M.S., Fraser, K.B. et al. (2015) Leucine-rich repeat kinase 2 (LRRK2) pharmacological inhibition abates α-synuclein gene-induced neurodegeneration. J. Biol. Chem. 290, 19433–19444, https://doi.org/10.1074/jbc.M115.660001

127 Korecký, J.A., Thomas, R., Hinrich, A.J., Moskites, A.M., Macbain, Z.K., Hallett, P.J. et al. (2020) Splice- Switching Antisense Oligonucleotides Reduce LRRK2 Kinase Activity in Human LRRK2 Transgenic Mice. Mol. Ther. – Nucleic Acids 21, 623–635, https://doi.org/10.1016/j.omtn.2020.06.027

128 Zhao, H.T., John, N., Delic, V., Ikeda-Lee, K., Kim, A., Weinhofen, A. et al. (2017) LRRK2 Antisense Oligonucleotides Ameliorate α-Synuclein Inclusion Formation in a Parkinson’s Disease Mouse Model. Mol. Ther. – Nucleic Acids 8, 508–519, https://doi.org/10.1016/j.omtn.2017.08.002

129 Marin, I. (2006) The Parkinson disease gene LRRK2: Evolutionary and structural insights. Mol. Biol. Evol. 23, 2423–2433, https://doi.org/10.1093/molbev/msf114

130 Marin, I. (2008) Ancient origin of the Parkinson disease gene LRRK2. J. Mol. Evol. 67, 41–50, https://doi.org/10.1007/s00239-008-9122-4

131 Force, A., Lynch, M., Pickett, F.B., Amores, A., Yan, Y. and Postlethwait, J. (1999) Preservation of Duplicte Genes by Complementary, Degenerative Mutations. Genetics 151, 1531–1545

132 Sämann, J., Hegermann, J., von Gromoff, E., Eimer, S., Baumeister, R. and Schmidt, E. (2009) Caenorhabditis elegans LRK-1 and PINK-1 act antagonistically in stress response and neurite outgrowth. J. Biol. Chem. 284, 16482–16491

133 Sakaguchi-Nakashima, A., Meir, J.Y., Jin, Y., Matsumoto, K. and Hisamoto, N. (2007) LRK-1, a C. elegans PARK8-Related Kinase, Regulates Axonal-Dendritic Polarity of SV Proteins. Curr. Biol. 17, 592–598, https://doi.org/10.1016/j.cub.2007.01.074

134 Reyniers, L., Del Giudice, M.G., Civiero, L., Belluzzi, E., Lobbestael, E., Bellina, A. et al. (2014) Differential protein-protein interactions of LRRK1 and LRRK2 indicate roles in distinct cellular signaling pathways. J. Neurochem. 131, 239–250, https://doi.org/10.1111/jn.12798

135 Tomkins, J.E., Dihanich, S., Bellina, A., Ferrari, R., Ilaqua, N., Cookson, M.R. et al. (2018) Comparative Protein Interaction Network Analysis Identifies Shared and Distinct Functions for the Human ROCO Proteins. Proteomics 18, 1–12

136 EMBOSS Stretcher < Pairwise Sequence Alignment < EMBL-EBI. Available from: https://www.ebi.ac.uk/Tools/psa/emboss_stretcher/<

137 Malik, A.U., Karapetsas, A., Nirujogi, R.S., Mathews, S., Chatterjee, D., Pal, P. et al. (2021) Deciphering the LRRK code: LRRK1 and LRRK2 phosphorylate distinct Rab proteins and are regulated by diverse mechanisms. Biochim. J. 478, 553–578

138 Iida, A., Xing, W., Dox, M.K.F., Nakashima, T., Wang, Z., Kimizuka, M. et al. (2016) Identification of biallelic LRRK1 mutations in osteosclerotic metaphyseal dysplasia and evidence for locus heterogeneity. J. Med. Genet. 53, 568–574

139 Mihonyesi, M., Nikfar, A., Changi-Ashiani, M., Shahrooei, M., Dimomhammadhi, H., Shahani, T. et al. (2020) A novel homozygous LRRK2 stop gain mutation in a patient suspected with osteosclerotic metaphyseal dysplasia. Ann. Hum. Genet. 84, 102–106, https://doi.org/10.1111/aeg.12352

140 Howaldt, A., Hennig, A.F., Rohviven, T., Rössler, U., Steiz, N., Knaus, A. et al. (2020) Adult Osteosclerotic Metaphyseal Dysplasia With Progressive Osteonecrosis of the Jaws and Abnormal Bone Resorption Pattern Due to a LRRK1 Splice Site Mutation. J. Bone Miner. Res. 35, 1322–1332, https://doi.org/10.1002/jbmr.3995

141 Yao, C., El Khoury, R., Wang, W., Byrd, T.A., Pehek, E.A., Thacker, C. et al. (2010) LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson’s disease. Neurobiol. Dis. 40, 73–81, https://doi.org/10.1016/j.nbd.2010.04.002

142 Luth, E.S., Stavrovskaya, I.G., Bartels, T., Kristal, B.S. and Selkoe, D.J. (2014) LRRK2 modulates vulnerability to mitochondrial dysfunction in C. elegans. J. Biol. Chem. 289, 21490–21507

143 Kamath, R.S., Fraser, A.G., Dong, Y., Poulin, G., Durbin, R., Gotta, M. et al. (2003) Systematic functional analysis of the Caenorhabditis elegans genome using RNAi. Nature 421, 231–237, https://doi.org/10.1038/nature01278

144 Blauwendraat, C., Reed, X., Kia, D.A., Gan-Or, Z., Lesage, S., Pihlstrøm, L. et al. (2018) Frequency of loss of function variants in LRRK2 in Parkinson disease. Nat. Med. 24, 869–877, https://doi.org/10.1038/s41591-020-0893-5

145 Fuji, R.N., Flagella, M., Baca, M., Baptista, M.A.S., Brodeck, J., Chan, B.K. et al. (2015) Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. Sci. Transl. Med. 7, 273, https://doi.org/10.1126/scitranslmed.aad3634

146 Reyniers, L., Del Giudice, M.G., Civiero, L., Belluzzi, E., Lobbestael, E., Bellina, A. et al. (2014) Differential protein-protein interactions of LRRK1 and LRRK2 indicate roles in distinct cellular signaling pathways. J. Neurochem. 131, 239–250, https://doi.org/10.1111/jn.12798

147 Saha, S., Guillity, M.D., Ferree, A., Lanceta, J., Chan, D., Ghosh, J. et al. (2009) LRRK2 modulates vulnerability to mitochondrial dysfunction in Caenorhabditis elegans. J. Neurosci. 29, 9210–9218, https://doi.org/10.1523/JNEUROSCI.2281-09.2009

148 Schaffner, A., Li, X., Gomez-Llorente, Y., Leandrou, E., Memou, A., Clemente, N. et al. (2019) Vitamin B12 modulates Parkinson’s disease LRRK2 kinase activity through allosteric regulation and confers neuroprotection. Cell Res. 29, 313–329

149 Langston, R.G., Rudenko, I.N., Kumaran, R., Hauser, D.N., Kaganovich, A., Ponce, L.B. et al. (2019) Differences in Stability, Activity and Mutation Effects Between Human and Mouse Lecine-Rich Repeat Kinase 2. Neurochem. Res. 44, 1446–1459, https://doi.org/10.1007/s11064-018-2650-4

150 Bieri, G., Bahram, M., Bousset, L., Couthouis, J., Kramer, N.J., Ma, R. et al. (2019) LRRK2 modifies α-syn pathology and spread in mouse models and human neurons. Acta Neuropathol. 137, 961–980, https://doi.org/10.1007/s00401-019-01995-0

151 Nguyen, A.P.T., Daniel, G., Valdés, P., Islam, M.S., Schneider, B.L. and Moore, D.J. (2018) G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain. Hum. Mol. Genet. 27, 120–134, https://doi.org/10.1093/hmg/ddx389

152 Kim, H., Perentis, R.J., Caldwell, G.A. and Caldwell, K.A. (2018) Gene-by-environment interactions that disrupt mitochondrial homeostasis cause neurodegeneration in C. elegans Parkinson’s models. Cell Death Dis. 9, 1–15, https://doi.org/10.1038/s41419-018-0619-5

153 Smith, L.L., Ryde, I.T., Hartman, J.H., Romersi, R.F., Markovich, Z. and Meyer, J.N. (2019) Strengths and limitations of morphological and behavioral analyses in detecting dopaminergic deficiency in Caenorhabditis elegans. Neurotoxicology 74, 209–220, https://doi.org/10.1016/j.neuro.2019.07.002
155 Ray, A., Martinez, B.A., Berkowitz, L.A., Caldwell, G.A. and Caldwell, K.A. (2014) Mitochondrial dysfunction, oxidative stress, and neurodegeneration elicited by a bacterial metabolite in a C. elegans Parkinson’s model. *Cell Death Dis.* 5, 984–1012, https://doi.org/10.1038/cdddis.2013.513

156 Wolozin, B., Saha, S., Guilley, M., Ferre, A. and Riley, M. (2008) Investigating convergent actions of genes linked to familial Parkinson’s disease. *Neurodegener Dis.* 5, 182–185, https://doi.org/10.1159/000113697

157 Deng, X., Dzamko, N., Prescott, A., Davies, P., Liu, Q., Yang, Q. et al. (2011) Characterization of a selective inhibitor of the Parkinson’s disease kinase LRRK2. *Nat. Chem. Biol.* 7, 203–205, https://doi.org/10.1038/nchembio.538

158 Yao, C., Johnson, W.M., Gao, Y., Wang, W., Zhang, J., Deak, M. et al. (2013) Kinase inhibitors arrest neurodegeneration in cell and C. elegans models of LRRK2 toxicity. *Hum. Mol. Genet.* 22, 328–344, https://doi.org/10.1093/hmg/ddz431

159 MacLeod, D.A., Rhinn, H., Kawai, A., Zolin, A., Di Paoli, G., MacCabe, B.D. et al. (2013) Rab7L1 Interacts with LRRK2 to Modulate Intraneuronal Protein Sorting and Parkinson’s Disease Risk. *Neuron* 77, 425–439

160 Choudhary, B., Kamak, M., Ratnakaran, N., Kumar, J., Awasthi, A., Li, C. et al. (2017) UNC-16/JIP3 regulates early events in synaptic vesicle protein trafficking via LRK-1/LRRK2 and AP complexes. *PLoS Genet.* 13, e1007100

161 Boecker, C.A., Goldsmith, J., Dou, D., Cajka, G.G. and Holzbaur, E.L.F. (2021) Increased LRRK2 kinase activity alters neuronal autophagy by disrupting the axonal transport of autophagosomes. *Curr. Biol.* 31, 2140–2145

162 Seol, W., Nam, D. and Son, I. (2019) Rab GTPases as physiological substrates of LRRK2 kinase. *Vol. 28*, Experimental Neurobiology.

163 Marchetti, B., Tirolo, C., L’Episcopo, F., Caniglia, S., Testa, N., Smith, J.A. et al. (2020) Parkinson’s disease, aging and adult neurogenesis: a Parkinson disease gene regulatory network identifies a regulator of Clathrin-mediated endocytosis. *Neurobiol. Dis.* 141, 104948

164 MacLeod, D.A., Rhinn, H., Kuwahara, T., Zolin, A., Di Paolo, G., MacCabe, B.D. et al. (2013) RAB7L1 Interacts with LRRK2 to Modify Intraneuronal Protein Sorting and Parkinson’s Disease Risk. *Neuron* 77, 425–439

165 Tomkins, J.E., Ferrari, R., Vavouraki, N., Hardy, J., Hardy, J., Hardy, J. et al. (2020) PINOT: An intuitive resource for integrating protein-protein interaction data. *Bioinformatics* 36, i134–i140, https://doi.org/10.1093/bioinformatics/btaa550

166 Prasad, B.C. (2006) Wnt signaling establishes anteroposterior neuronal polarity and requires retromer in C. elegans. *Aging Cell.* 5, 181–189, https://doi.org/10.1111/j.1440-1695.2005.00248.x

167 Gorenberg, E.L. and Chandra, S.S. (2017) The role of co-chaperones in synaptic proteostasis and neurodegenerative disease. *Aging Cell.* 16, 1–19, https://doi.org/10.1111/acel.13101

168 Marchetti, B., Tirolo, C., L’Episcopo, F., Caniglia, S., Testa, N., Smith, J.A. et al. (2020) Parkinson’s disease, aging and adult neurogenesis: a Parkinson disease gene regulatory network identifies a regulator of Clathrin-mediated endocytosis. *Neurobiol. Dis.* 141, 104948

169 Madero-P´erez, J., Fern´andez, B., Lara Ord´o˜nez, A.J., Fdez, E., Lobbestael, E., Baekelandt, V. et al. (2018) RAB7L1-mediated relocalization of LRRK2 to the golgi complex causes centrosomal deficits via RAB8A. *Front. Mol. Neurosci.* 11, 1–19, https://doi.org/10.3389/fnmol.2018.00417

170 Harterink, M., Kim, D.H., Middelkoop, T.C., Doan, T.D., van Oudenaarden, A. and Korswagen, H.C. (2011) Neuroblast migration along the axonal transport of autophagosomes. *Front. Mol. Neurosci.* 4, 359–366, https://doi.org/10.3389/fnmol.2011.00388

171 Sancho, R.M., Law, B.M.H. and Harvey, K. (2009) Mutations in the LRRK2 Roc-COR tandem domain link Parkinson’s disease to Wnt signalling. *Hum. Mol. Genet.* 18, 819–831, https://doi.org/10.1093/hmg/ddn202

172 Prasad, B.C. (2006) Wnt signaling establishes anteroposterior neuronal polarity and requires retromer in C. elegans. *Development* 133, 1757–1766, https://doi.org/10.1242/dev.02357

173 Prasad, B.C. (2006) Wnt signaling establishes anteroposterior neuronal polarity and requires retromer in C. elegans. *Development* 133, 1757–1766, https://doi.org/10.1242/dev.02357

174 Prasad, B.C. (2006) Wnt signaling establishes anteroposterior neuronal polarity and requires retromer in C. elegans. *Development* 133, 1757–1766, https://doi.org/10.1242/dev.02357

175 Dusonchet, J., Li, H., Guillily, M., Liu, M., Stafa, K., Derada Troletti, C. et al. (2014) A Parkinson’s disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity. *Hum. Mol. Genet.* 23, 4887–4905, https://doi.org/10.1093/hmg/ddu202

176 Fukuzono, T., Pastuhov, S.I., Fukushima, O., Li, C., Hattori, A., Iemura, Shun-ichiro et al. (2016) Chaperone complex BAG2-HSC70 regulates localization of Caenorhabditis elegans leucine-rich repeat kinase LRK-1 to the Golgi. *Genes Cells* 21, 311–324, https://doi.org/10.1111/gtc.12338

177 Deng, X., Dzamko, N., Prescott, A., Davies, P., Liu, Q., Yang, Q. et al. (2011) Characterization of a selective inhibitor of the Parkinson’s disease kinase LRRK2. *Nat. Chem. Biol.* 7, 203–205, https://doi.org/10.1038/nchembio.538

178 Liu, Z., Bryant, N., Kumar, R., Bellina, A., Abbeiiovich, A., Cookson, M.R. et al. (2018) LRRK2 phosphorylates membrane-bound Rabs and is activated by GTP-bound Rab7L1 to promote recruitment to the trans-Golgi network. *Hum. Mol. Genet.* 27, 385–395, https://doi.org/10.1093/hmg/ddx410

179 Puryte, E., Dhekne, H.S., Sarhan, A.R., Gomez, R., Lis, P., Wightman, M. et al. (2018) Rab29 activation of the Parkinson’s disease-associated LRRK2 kinase. *EMBO J.* 37, 1–18, https://doi.org/10.15252/embj.201798099

180 Madero-P´erez, J., Fern´andez, B., Lara Ord´o˜nez, A.J., Fdez, E., Lobbestael, E., Baekelandt, V. et al. (2018) RAB7L1-mediated relocalization of LRRK2 to the golgi complex causes centrosomal deficits via RAB8A. *Front. Mol. Neurosci.* 11, 1–19, https://doi.org/10.3389/fnmol.2018.00417
241 Xilouri, M., Brekk, O.R. and Stefanis, L. (2016) Autophagy and Alpha-Synuclein: Relevance to Parkinson’s disease and Related Synucleopathies. *Mov. Disord.* **31**, 178–192, https://doi.org/10.1002/mds.26477

242 Liu, J., Wang, X., Lu, Y., Duan, C., Gao, G., Lu, L. et al. (2017) Pink1 interacts with α-synuclein and abrogates α-synuclein-induced neurotoxicity by activating autophagy. *Cell Death Dis.* **8**, e3056, https://doi.org/10.1038/cddis.2017.427

243 da Fonseca, T.L., Pinho, R. and Outeiro, T.F. (2016) A familial ATP13A2 mutation enhances alpha-synuclein aggregation and promotes cell death. *Hum. Mol. Genet.* **25**, 2595–2571, https://doi.org/10.1093/hmg/ddw147

244 Miura, E., Hasegawa, T., Konno, M., Suzuki, M., Sugeno, N., Fujikake, N. et al. (2014) VPS35 dysfunction impairs lysosomal degradation of α-synuclein and exacerbates neurotoxicity in a Drosophila model of Parkinson’s disease. *Neurobiol. Dis.* **71**, 1–13, https://doi.org/10.1016/j.nbd.2014.07.014

245 Kamp, F., Exner, N., Lutz, A.K., Wender, N., Hegermann, J., Brunner, B. et al. (2010) Inhibition of mitochondrial fusion by α-synuclein is rescued by PINK1, Parkin and DJ-1. *EMBO J.* **29**, 3571–3589, https://doi.org/10.1038/emboj.2010.223

246 Lakso, M., Vartiainen, S., Molinan, A.M., Sirvio, J., Thomas, J.H., Nass, R. et al. (2003) Dopaminergic neuronal loss and motor deficits in Caenorhabditis elegans overexpressing human α-synuclein. *J. Neurochem.* **86**, 165–172, https://doi.org/10.1046/j.1471-4159.2003.01809.x

247 Kuwahara, T., Koyama, A., Gengyo-Ando, K., Masuda, M., Kowa, H., Tsunoda, M. et al. (2006) Familial Parkinson mutant α-synuclein causes dopamine neuron dysfunction in transgenic Caenorhabditis elegans. *J. Biol. Chem.* **281**, 334–340

248 Gaeta, A.L., Caldwell, K.A. and Caldwell, G.A. (2019) Found in translation: The utility of C. elegans Alpha-Synuclein models of Parkinson’s disease. *Brain Sci.* **9**, 73, https://doi.org/10.3390/brainsci9040073

249 Jadiya, P., Fatima, S., Baghel, T., Mir, S.S. and Nazir, A. (2016) A Systematic RNAi Screen of Neuroprotective Genes Identifies Novel Modulators of Alpha-Synuclein-Associated Effects in Transgenic Caenorhabditis elegans. *Mol. Neurobiol.* **53**, 6288–6300, https://doi.org/10.1007/s12035-015-9517-3

250 Due, D.J. and Moore, D.J. (2020) LRRK2 and Protein Aggregation in Parkinson’s Disease: Insights From Animal Models. *Front. Neurosci.* **14**

251 Liu, G., Aliaga, L. and Cai, H. (2012) Mutation of hop-1 and pink-1 attenuates vulnerability of neurotoxicity in C. elegans: the role of mitochondria-associated membrane proteins in Parkinsonism. *Exp. Neurol.* **309**, 67–78, https://doi.org/10.1016/j.expneurol.2018.07.018
268 Luz, A.L., Rooney, J.P., Kubik, L.L., Gonzalez, C.P., Song, D.H. and Meyer, J.N. (2015) Mitochondrial morphology and fundamental parameters of the mitochondrial respiratory chain are altered in caenorhabditis elegans strains deficient in mitochondrial dynamics and homeostasis processes. PLoS One 10, 1–23, https://doi.org/10.1371/journal.pone.0130940

269 Chakraborty, S., Chen, P., Bornhorst, J., Schwerdtle, T., Schumacher, F., Kleuser, B. et al. (2015) Loss of pdr-1/parkin influences Mn homeostasis through altered ferroportin expression in C. elegans. Metallomics 7, 847–856, https://doi.org/10.1039/C5MT00052A

270 Asikainen, S., Rudgalvyte, M., Heikkinen, L., Louhiranta, K., Lakso, M., Wong, G. et al. (2010) Global microRNA expression profiling of caenorhabditis elegans Parkinson’s disease models. J. Mol. Neurosci. 41, 210–218, https://doi.org/10.1007/s12031-009-9325-1

271 Erb, M.L. and Moore, D.J. (2020) LRRK2 and the Endolysosomal System in Parkinson’s Disease. J Parkinsons Dis. 10, 1271–1291, https://doi.org/10.3233/JPD-202138

272 Cogo, S., Manzoni, C., Lewis, P.A. and Greggio, E. (2020) Leucine-rich repeat kinase 2 and lysosomal dyshomeostasis in Parkinson disease. J. Neurochem. 152, 273–283, https://doi.org/10.1111/jnc.14908

273 Orenstein, S.J., Kuo, S.H., Tasset, I., Arias, E., Koga, H., Fernandez-Carasa, I. et al. (2013) Interplay of LRRK2 with chaperone-mediated autophagy. Nat. Neurosci. 16, 394–406, https://doi.org/10.1038/nn.3350

274 Chia, S.J., Tan, E.K. and Chao, Y.X. (2020) Historical perspective: Models of Parkinson’s disease. Int. J. Mol. Sci. 21, 1–14